Cargando…

The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients

BACKGROUND: The American Fistula First Breakthrough Initiative currently aims for a 66% arterio-venous fistula (AVF) rate, while in the UK, best practice tariffs target AVF and arterio-venous graft (AVG) rates of 85%. The present study aims to assess whether these goals can be achieved. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Praehauser, Claudia, Breidthardt, Tobias, Moser-Bucher, Cora Nina, Wolff, Thomas, Baechler, Katrin, Eugster, Thomas, Dickenmann, Michael, Gurke, Lorenz, Mayr, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393467/
https://www.ncbi.nlm.nih.gov/pubmed/25874094
http://dx.doi.org/10.1093/ckj/sfs055
_version_ 1782366159746629632
author Praehauser, Claudia
Breidthardt, Tobias
Moser-Bucher, Cora Nina
Wolff, Thomas
Baechler, Katrin
Eugster, Thomas
Dickenmann, Michael
Gurke, Lorenz
Mayr, Michael
author_facet Praehauser, Claudia
Breidthardt, Tobias
Moser-Bucher, Cora Nina
Wolff, Thomas
Baechler, Katrin
Eugster, Thomas
Dickenmann, Michael
Gurke, Lorenz
Mayr, Michael
author_sort Praehauser, Claudia
collection PubMed
description BACKGROUND: The American Fistula First Breakthrough Initiative currently aims for a 66% arterio-venous fistula (AVF) rate, while in the UK, best practice tariffs target AVF and arterio-venous graft (AVG) rates of 85%. The present study aims to assess whether these goals can be achieved. METHODS: We conducted a retrospective cohort study on patients who initiated haemodialysis from 1995 to 2006. Outcomes were the final failure-free survival of the first permanent access and the type of second access created. Prevalent use rates for the access types were calculated on the 1st January of each year for the second half of the study period. RESULTS: Two hundred and eleven out of 246 patients (86%) received an AVF, 16 (6%) an AVG and 19 (8%) a permanent catheter (PC) as the first permanent access. Eighty-six (35%) patients had final failure of the primary access. One- and 3-year final failure-free survival rates were 73 and 65% for AVF compared with 40 and 20% for AVG and 62 and 0% for PC, respectively. In patients with primary AVF, female sex {hazard ratio (HR) 2.20 [confidence interval (CI) 1.29–3.73]} and vascular disease [HR 2.24 (CI 1.26–3.97)] were associated with a poorer outcome. A similar trend was observed for autoimmune disease [HR 2.14 (CI 0.99–4.65)]. As second accesses AVF, AVG and PC were created in 47% (n = 40), 38% (n = 33) and 15% (n = 13). The median prevalent use rate was 80.5% for AVF, 14% for AVG and 5.5% for PC. CONCLUSIONS: The vascular access targets set by initiatives from the USA and UK are feasible in unselected haemodialysis patients. High primary AVF rates, the superior survival rates of AVFs even in patient groups at higher risk of access failure and the high rate of creation of secondary AVFs contributed to these promising results.
format Online
Article
Text
id pubmed-4393467
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43934672015-04-13 The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients Praehauser, Claudia Breidthardt, Tobias Moser-Bucher, Cora Nina Wolff, Thomas Baechler, Katrin Eugster, Thomas Dickenmann, Michael Gurke, Lorenz Mayr, Michael Clin Kidney J Clinical Cases BACKGROUND: The American Fistula First Breakthrough Initiative currently aims for a 66% arterio-venous fistula (AVF) rate, while in the UK, best practice tariffs target AVF and arterio-venous graft (AVG) rates of 85%. The present study aims to assess whether these goals can be achieved. METHODS: We conducted a retrospective cohort study on patients who initiated haemodialysis from 1995 to 2006. Outcomes were the final failure-free survival of the first permanent access and the type of second access created. Prevalent use rates for the access types were calculated on the 1st January of each year for the second half of the study period. RESULTS: Two hundred and eleven out of 246 patients (86%) received an AVF, 16 (6%) an AVG and 19 (8%) a permanent catheter (PC) as the first permanent access. Eighty-six (35%) patients had final failure of the primary access. One- and 3-year final failure-free survival rates were 73 and 65% for AVF compared with 40 and 20% for AVG and 62 and 0% for PC, respectively. In patients with primary AVF, female sex {hazard ratio (HR) 2.20 [confidence interval (CI) 1.29–3.73]} and vascular disease [HR 2.24 (CI 1.26–3.97)] were associated with a poorer outcome. A similar trend was observed for autoimmune disease [HR 2.14 (CI 0.99–4.65)]. As second accesses AVF, AVG and PC were created in 47% (n = 40), 38% (n = 33) and 15% (n = 13). The median prevalent use rate was 80.5% for AVF, 14% for AVG and 5.5% for PC. CONCLUSIONS: The vascular access targets set by initiatives from the USA and UK are feasible in unselected haemodialysis patients. High primary AVF rates, the superior survival rates of AVFs even in patient groups at higher risk of access failure and the high rate of creation of secondary AVFs contributed to these promising results. Oxford University Press 2012-08 2012-06-28 /pmc/articles/PMC4393467/ /pubmed/25874094 http://dx.doi.org/10.1093/ckj/sfs055 Text en © The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Cases
Praehauser, Claudia
Breidthardt, Tobias
Moser-Bucher, Cora Nina
Wolff, Thomas
Baechler, Katrin
Eugster, Thomas
Dickenmann, Michael
Gurke, Lorenz
Mayr, Michael
The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients
title The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients
title_full The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients
title_fullStr The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients
title_full_unstemmed The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients
title_short The outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients
title_sort outcome of the primary vascular access and its translation into prevalent access use rates in chronic haemodialysis patients
topic Clinical Cases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393467/
https://www.ncbi.nlm.nih.gov/pubmed/25874094
http://dx.doi.org/10.1093/ckj/sfs055
work_keys_str_mv AT praehauserclaudia theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT breidthardttobias theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT moserbuchercoranina theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT wolffthomas theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT baechlerkatrin theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT eugsterthomas theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT dickenmannmichael theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT gurkelorenz theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT mayrmichael theoutcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT praehauserclaudia outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT breidthardttobias outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT moserbuchercoranina outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT wolffthomas outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT baechlerkatrin outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT eugsterthomas outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT dickenmannmichael outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT gurkelorenz outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients
AT mayrmichael outcomeoftheprimaryvascularaccessanditstranslationintoprevalentaccessuseratesinchronichaemodialysispatients